Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge acted as local counsel in relation to the sale of Phadia, the biotechnology company, for SEK 22 billion
Mandate

Vinge acted as local counsel in relation to the sale of Phadia, the biotechnology company, for SEK 22 billion

May 20, 2011

Cinven has entered into an agreement with Thermo Fisher Scientific to sell the Uppsala based biotechnology company, Phadia Group, for SEK 22 billion. Phardia is a spin-off from the former Pharmacia and enjoys a leading position within allergy testing.

Vinge acted as local counsel advising on Swedish legal issues for Cinven/Freshfields. Vinge's team consisted of partner Christina Kokko and associates Joacim Rydergård, Jonas Bergström, Alex Miller and Albert Wållgren.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

 Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026

Vinge has advised IK Partners in connection with the acquisition of Selatek

 Vinge has advised IK Partners (“IK”) in connection with IK X Fund’s acquisition of SELATEK Holding AB (“Selatek”), a leading Swedish technical installation platform, from Amplio Private Equity AB and the minority shareholders.
April 20, 2026